Heghine Khachatryan: Addressing Critical Gaps in Cancer-Associated VTE
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from RPTH Journal on LinkedIn, adding:
”Cancer-associated VTE: an old problem, still unresolved
Despite decades of research, cancer-associated venous thromboembolism (VTE) remains a major cause of morbidity and mortality.
This timely editorial in Research and Practice in Thrombosis and Haemostasis highlights critical gaps—from real-time epidemiologic data to optimal thromboprophylaxis and bleeding risk stratification—and points toward future, cancer-specific solutions.
A strong reminder that prevention, individualized risk assessment, and innovation in anticoagulation must remain a global priority in oncology and hematology.
Editorial by Alok Khorana
Research and Practice in Thrombosis and Haemostasis”
Quoting RPTH Journal‘s post:
”Cancer-associated VTE: an old problem, still unresolved
RPTH Journal Editorial by Alok Khorana
As highlighted by Maiocco et al. in RPTH Journal, it remains puzzling that VTE, a complication of cancer known since the 19th century, continues to heavily burden modern oncology care.
- Cancer patients face a 9- to 20-fold higher risk of VTE, even with contemporary therapies
- In a nationwide US inpatient analysis, 8.1% of cancer-related hospitalizations were complicated by VTE
- VTE remains strongly associated with higher mortality, longer hospital stays, and higher costs
- Despite decades of awareness, robust evidence for inpatient thromboprophylaxis in cancer patients is still lacking
Read the editorial here
Read the study by Giuseppe Maiocco et al here”
Title: The public health impact of cancer-associated venous thromboembolism: looking to the future
Authors: Alok Khorana
Read the Full Editorial on RPTH Journal

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 11:28Kalyan Roy: A New Era in Thalassemia Treatment – FDA Approves Mitapivat
-
Nov 14, 2026, 11:24Can Iron Deficiency Really be Seen in Someone’s Face? – ASH
-
Nov 14, 2026, 11:19Lindsay Davison: Putting Childhood Anemia in the Spotlight with IronUp and Danone
-
Nov 14, 2026, 10:00Benjamin Tur: Putting Iron Deficiency Anemia on the Global Agenda at the Paris Peace Forum’s Child Summit
-
Nov 14, 2026, 09:48Jack Shuang Hou: FDA Approves Bayer’s Sunharbo – First Factor XIa Inhibitor for Secondary Stroke Prevention
-
Nov 14, 2026, 09:42Samwel Mikaye: What Every Patient Should Know About DVT Symptoms and Treatment
-
Nov 14, 2026, 09:37Chronic Preoperative Corticosteroid Use and Postoperative Venous Thromboembolism Risk – Thrombosis and Haemostasis Journal
-
Nov 14, 2026, 09:30Ney Carter Borges: Vulnerable Plaque – Imaging and Clinical Significance
-
Nov 14, 2026, 09:25Carmelo Raffo: How Much Antithrombotic Therapy is Truly Necessary after LAAC?